Výsledky vyhledávání - Hui‐Ling Zhen

  • Zobrazuji výsledky 1 - 12 z 12
Upřesnit hledání
  1. 1
    Clinicogenomic Analysis of <i>FGFR2</i>-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

    Clinicogenomic Analysis of <i>FGFR2</i>-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib Autor Ian M. Silverman, Antoine Hollebecque, Luc Friboulet, Sherry Owens, Robert Newton, Hui‐Ling Zhen, Luis Féliz, Camilla Zecchetto, Davide Melisi, Timothy C. Burn

    Vydáno 2020
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)

    Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harbori... Autor Andrea Necchi, Damien Pouessel, Raya Leibowitz‐Amit, Aude Fléchon, Sumati Gupta, Philippe Barthélémy, Michele Maio, Xinhua Zhu, Ekatherine Asatiani, Gul Serbest, Hui‐Ling Zhen, Yohann Loriot

    Vydáno 2018
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN <i>FGFR1</i>)

    A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN <i>FGF... Autor Jason Gotlib, Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Alessandro Rambaldi, Andreas Reiter, William Shomali, Tracy I. George, Jay Patel, Philomena Colucci, Chris Walker, Hui‐Ling Zhen, Srđan Verstovšek

    Vydáno 2021
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

    Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results Autor Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Hui‐Ling Zhen, Muriel Granier, Albert Assad, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi

    Vydáno 2017
    Získat plný text Získat plný text
    Carta
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy

    Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy Autor Ruben A. Mesa, Srđan Verstovšek, Jean‐Jacques Kiladjian, Martin Grießhammer, Tamás Masszi, Simon Durrant, Francesco Passamonti, Claire Harrison, Fabrizio Pane, Pierre Zachée, Hui‐Ling Zhen, Mark M. Jones, Shreekant Parasuraman, Jingjin Li, Isabelle Côté, Dany Habr, Alessandro M. Vannucchi

    Vydáno 2015
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF)

    The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom... Autor Ruben A. Mesa, Alessandro M. Vannucchi, Abdulraheem Yacoub, Pierre Zachée, Mamta Garg, Roger M. Lyons, Steffen Koschmieder, Ciro R. Rinaldi, Jenny Byrne, Yasmin Hasan, Francesco Passamonti, Srđan Verstovšek, Deborah Hunter, Mark M. Jones, Hui‐Ling Zhen, Dany Habr, Bruno Martino

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements

    FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements Autor Tanios Bekaii‐Saab, Juan W. Valle, Eric Van Cutsem, Lorenza Rimassa, Junji Furuse, Tatsuya Ioka, Davide Melisi, Teresa Macarulla, John Bridgewater, Harpreet Wasan, Mitesh J. Borad, Ghassan K. Abou‐Alfa, Ping Jiang, Christine Lihou, Hui‐Ling Zhen, Ekaterine Asatiani, Luis Féliz, Arndt Vogel

    Vydáno 2020
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202

    An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202 Autor Arndt Vogel, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed MAl Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David Gallinson, Adrian Murphy, Do‐Youn Oh, Efrat Dotan, Daniel V.T. Catenacci, E. Van Cutsem, Christine Lihou, Hui‐Ling Zhen, M L Veronese, G.K. Abou-Alfa

    Vydáno 2024
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)

    FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) Autor Arndt Vogel, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed Moh’d Taiseer Al-Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David Gallinson, Adrian Murphy, Do‐Youn Oh, Efrat Dotan, Daniel V.T. Catenacci, Eric Van Cutsem, Christine Lihou, Hui‐Ling Zhen, Luis Féliz, Ghassan K. Abou‐Alfa

    Vydáno 2019
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

    Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study Autor Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed Moh’d Taiseer Al-Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David Gallinson, Adrian Murphy, Do‐Youn Oh, Efrat Dotan, Daniel V.T. Catenacci, Eric Van Cutsem, Tao Ji, Christine Lihou, Hui‐Ling Zhen, Luis Féliz, Arndt Vogel

    Vydáno 2020
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

    Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial Autor Srđan Verstovšek, A. M. Vannucchi, Martin Grießhammer, Tamás Masszi, Simon Durrant, Francesco Passamonti, C. N. Harrison, Fabrizio Pane, Pierre Zachée, Keita Kirito, Carlos Besses, Masayuki Hino, Beatriz Moiraghi, Carole B. Miller, M. Cazzola, Vittorio Rosti, I. Blau, Ruben A. Mesa, Mark M. Jones, Hui‐Ling Zhen, Li J, Nathalie Francillard, Dany Habr, Jean‐Jacques Kiladjian

    Vydáno 2016
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

    Truncated FGFR2 is a clinically actionable oncogene in multiple cancers Autor Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M. Kas, Frank Rolfs, Catrin Lutz, Jessica Lee, Sjoerd Klarenbeek, Ian M. Silverman, Stefano Annunziato, Chang S. Chan, Sander R. Piersma, Timo Eijkman, Madelon Badoux, Ewa Gogola, Bjørn Siteur, Justin Sprengers, Bim de Klein, Richard R. de Goeij‐de Haas, Gregory Riedlinger, Hua Zhu Ke, Russell W. Madison, Anne Paulien Drenth, Eline van der Burg, Eva Schut, Linda Henneman, Martine H. van Miltenburg, Natalie Proost, Hui‐Ling Zhen, Ellen Wientjens, Roebi de Bruijn, Julian R. de Ruiter, Ute Boon, Renske de Korte‐Grimmerink, Bastiaan van Gerwen, Luis Féliz, Ghassan K. Abou‐Alfa, Jeffrey S. Ross, Marieke van de Ven, Sven Rottenberg, Edwin Cuppen, Anne Vaslin Chessex, Siraj M. Ali, Timothy C. Burn, Connie R. Jiménez, Shridar Ganesan, Lodewyk F.A. Wessels, Jos Jonkers

    Vydáno 2022
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: